Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.33 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $0.69 for the same period compares to $0.60 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $4.08 billion, representing a surprise of +6.12%. The company delivered an EPS surprise of +6.15%, with the consensus EPS estimate being $0.65.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- International Markets: $613 million versus $615.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change.
• Geographic Revenue- United States: $2.23 billion versus the four-analyst average estimate of $2.06 billion. The reported number represents a year-over-year change of +11.1%.
• Geographic Revenue- United States- COPAXONE: $69 million versus $49.93 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change.
• Geographic Revenue- United States- BENDEKA / TREANDA: $40 million versus $38.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -29.8% change.
• Geographic Revenue- United States- AUSTEDO: $435 million versus the four-analyst average estimate of $436.83 million. The reported number represents a year-over-year change of +28.3%.
• Geographic Revenue- United States- Anda: $380 million versus the four-analyst average estimate of $351.57 million. The reported number represents a year-over-year change of +3.5%.
• Geographic Revenue- Europe- COPAXONE: $53 million versus the four-analyst average estimate of $47.56 million. The reported number represents a year-over-year change of -3.6%.
• Geographic Revenue- Europe- Respiratory products: $60 million versus the four-analyst average estimate of $57.37 million. The reported number represents a year-over-year change of -1.6%.
• Geographic Revenue- International Markets- Generic products: $477 million versus the four-analyst average estimate of $497.41 million. The reported number represents a year-over-year change of +25.2%.
• Geographic Revenue- International Markets- COPAXONE: $13 million versus $12.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30% change.
• Geographic Revenue- United States- AJOVY: $58 million compared to the $56.34 million average estimate based on four analysts. The reported number represents a change of -4.9% year over year.
• Geographic Revenue- Europe- Generic products: $973 million versus the four-analyst average estimate of $930.59 million. The reported number represents a year-over-year change of +9.8%.

View all Key Company Metrics for Teva Pharmaceutical Industries here>>>

Shares of Teva Pharmaceutical Industries have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research